Core Viewpoint - The article highlights the recent movements of social security funds in the A-share market, revealing that they have newly entered the top ten circulating shareholders of 63 companies in the third quarter of 2025, indicating a strategic investment shift towards certain sectors and companies [1]. Group 1: New Holdings by Social Security Funds - Social security funds have newly entered the top ten shareholders of companies such as Huace Navigation, Enhua Pharmaceutical, Zhuoyi Information, Huazheng New Materials, Sankeshu, and Xinmei Shares, with each having two new holdings [1]. - A total of 63 companies saw new investments from social security funds, with notable mentions including Dazhu Laser, Zhongke Environmental Protection, Shenhuo Co., Ltd., and others, each having one new holding [1]. Group 2: Financial Performance of Key Companies - Huace Navigation reported a revenue of 2.618 billion yuan for the first three quarters, a year-on-year increase of 15.47%, and a net profit of 493 million yuan, up 26.41% [4]. - Enhua Pharmaceutical achieved a revenue of 4.471 billion yuan, reflecting a 7.85% year-on-year growth, and a net profit of 1.106 billion yuan, which is an 8.42% increase [5]. - Dazhu Laser's revenue for the first three quarters reached 12.713 billion yuan, marking a 25.51% increase, while its net profit was 863 million yuan, a decrease of 39.46% [6]. Group 3: Sector Insights - The sectors represented by the newly invested companies include satellite applications, chemical preparations, industry application software, electronic components, coatings, and network television, indicating a diverse investment strategy by social security funds [2][3]. - The pharmaceutical sector, particularly CNS (central nervous system) drugs, is highlighted as having significant market potential, with Enhua Pharmaceutical's pipeline being compared to overseas blockbuster products [5].

Core Insights - Enhua Pharmaceutical (002262.SZ) released its Q3 2025 report on October 25, 2025, indicating a total of 356 million shares held by institutional investors, accounting for 35.08% of the company's total equity [1] - The institutional holding percentage decreased by 2.55 percentage points compared to the previous quarter [1] Institutional Holdings - Five institutional investors disclosed their holdings in Enhua Pharmaceutical, including Xuzhou Enhua Investment Co., Hong Kong Central Clearing Limited, and two national social security fund combinations [1] - One new public fund was disclosed this quarter, while 323 public funds were not disclosed compared to the previous quarter [1] Social Security Fund - Two new social security funds disclosed their holdings in Enhua Pharmaceutical, while one fund was not disclosed compared to the previous quarter [1] Foreign Investment - One new foreign institution, Hong Kong Central Clearing Limited, disclosed its holdings this quarter [1]

Core Insights - Enhua Pharmaceutical reported a revenue of 1,460,867,102.85 yuan for Q3 2025, representing a year-on-year growth of 5.70% [1] - The net profit attributable to shareholders of the listed company was 405,552,659.33 yuan, showing a year-on-year increase of 3.67% [1]

Core Viewpoint - Enhua Pharmaceutical reported a revenue of 4.471 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders reached 1.106 billion yuan, marking an increase of 8.42% compared to the previous year [1] Financial Performance - Revenue for the first three quarters: 4.471 billion yuan, up 7.85% year-on-year [1] - Net profit attributable to shareholders: 1.106 billion yuan, up 8.42% year-on-year [1]

Group 1 - Enhua Pharmaceutical held its seventh fourth board meeting on October 24, 2025, in Xuzhou, where the third quarter report for 2025 was reviewed [1] - The company reported that it has sold overseas authorizations worth $80 billion in the current year [1] - The secondary market for biopharmaceuticals is experiencing a surge, while the primary market is facing challenges in fundraising [1]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 4.471 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders of the listed company reached 1.106 billion yuan, with a year-on-year increase of 8.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.109 billion yuan, reflecting a year-on-year growth of 7.59% [1]

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a revenue of 4.47 billion yuan for the first three quarters, representing a year-on-year growth of 7.85% [1] - The net profit attributable to shareholders reached 1.106 billion yuan, with a year-on-year increase of 8.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.109 billion yuan, reflecting a year-on-year growth of 7.59% [1]

人民财讯10月24日电，恩华药业(002262)10月24日披露2025年三季度报告，公司第三季度实现营业收入 14.61亿元，同比增长5.70%；归母净利润4.06亿元，同比增长3.67%。前三季度实现营业收入44.71亿 元，同比增长7.85%；归母净利润11.06亿元，同比增长8.42%。 转自：证券时报 ...

Core Insights - Enhua Pharmaceutical reported Q3 revenue of 1.461 billion yuan, a year-on-year increase of 5.70% [1] - The net profit for Q3 was 406 million yuan, reflecting a year-on-year growth of 3.67% [1] - For the first three quarters, the total revenue reached 4.471 billion yuan, up by 7.85% year-on-year [1] - The net profit for the first three quarters was 1.106 billion yuan, showing an increase of 8.42% year-on-year [1]

第七届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 江苏恩华药业股份有限公司（以下简称：公司）监事会于2025年10月13日以电子邮 件及专人送达的方式向全体监事发出召开第七届监事会第四次会议的通知及相关会议资 料。2025年10月24日下午1：00至3：00，第七届监事会第四次会议在徐州市经济技术开 发区龙湖西路31号恩华科技大厦20楼会议室以现场表决的方式召开，公司3名监事全部参 加了会议。本次会议由监事会主席王丰收先生主持。本次会议的召集、召开程序符合有 关法律法规和公司章程的规定。 二、监事会会议审议情况 1、会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2025年第三季 度报告》。 证券代码：002262 证券简称：恩华药业 公告编号：2025-052 江苏恩华药业股份有限公司 经审核，监事会认为：董事会编制和审核公司2025年第三季度报告的程序符合法律、 行政法规和中国证监会的有关规定，报告内容真实、准确、完整地反映了报告期内公司 的财务状况、经营成果和现金流量，不存在任何虚假记载、 ...